Home / Health / Revolutionary Compound Fights Malaria, Bacteria, Fungi
Revolutionary Compound Fights Malaria, Bacteria, Fungi
2 Sep
Summary
- New chemical compounds patented by MSU researchers show promise.
- Compounds target malaria, bacterial, and fungal infections simultaneously.
- Developed molecular framework differs from conventional anti-infective drugs.
Researchers at Mississippi State University (MSU) have secured an Indian patent for a new category of chemical compounds engineered to fight multiple infectious diseases. The innovation developed at the Department of Applied Chemistry introduces a unique molecular framework that diverges from traditional anti-malarial drug designs.
This patented framework is a hybrid structure combining coumarin, sulfonamide, and piperazine chemical building blocks. Laboratory investigations revealed significant activity against the malaria parasite (Plasmodium falciparum) and common pathogens like Pseudomonas aeruginosa, Candida albicans, and Aspergillus niger.
The synthesized compounds demonstrated antimalarial efficacy comparable to chloroquine. Researchers propose that these compounds may target the dihydrofolate reductase (DHFR) enzyme, crucial in folate metabolism and a key target for infectious disease treatments, suggesting broad-spectrum anti-infective potential.
While these findings present exciting possibilities for developing multi-target anti-infective drugs, the compounds are still in the research and development phase. Further detailed studies are ongoing to assess potential side effects before they can be considered established medicines.
